Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stefanie Raith"'
Autor:
Alfred Zippelius, Mélanie Buchi, Richard Klar, Julia Festag, Monika Schell, Sven Michel, Frank Jaschinski, Nicole Kirchhammer, Andre Maaske, Laura Fernandez Rodriguez, Stefanie Raith
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8d9deaf4680c4b0188ce465ba98d44a2
Autor:
Julia Festag, Tamara Thelemann, Monika Schell, Stefanie Raith, Sven Michel, Frank Jaschinski, Richard Klar
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss , Pp 656-669 (2020)
The adenosine axis contributes to the suppression of antitumor immune responses. The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73. Adenosine binds t
Externí odkaz:
https://doaj.org/article/42e8450dd8f7414f8e521a6e5f56c509
Autor:
Richard Klar, Clara Seger, Nicole Kirchhammer, André Maaske, Julia Festag, Laura Fernandez Rodriguez, Mélanie Buchi, Monika Schell, Stefanie Raith, Sven Michel, Alfred Zippelius, Frank Jaschinski
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Sven Michel, Stefanie Raith, Monika Schell, Frank Jaschinski, Tamara Thelemann, Richard Klar, Julia Festag
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 656-669 (2020)
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 656-669 (2020)
The adenosine axis contributes to the suppression of antitumor immune responses. The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73. Adenosine binds t
Autor:
Andre Maaske, Nicole Kirchhammer, Julia Festag, Laura Fernandez Rodriguez, Mélanie Buchi, Monika Schell, Stefanie Raith, Sven Michel, Richard Klar, Alfred Zippelius, Frank Jaschinski
Publikováno v:
Cancer Research. 82:4149-4149
Immune checkpoint inhibitors have become an important tool for the treatment of cancer. However, the majority of patients does not respond to the currently employed antibody-based treatments, indicating a need for additional targets and new treatment
Autor:
Richard Klar, Stefanie Raith, Yu Cao, Eslam Mohamed, Frank Jaschinski, Lisa Hinterwimmer, Monika Schell, Paulo C. Rodriguez, Sven Michel
Publikováno v:
Cancer Research. 79:3275-3275
The microenvironment generated by tumor cells and suppressive stromal cells creates unfavorable conditions for effector immune cells in order to escape anti-tumor immunity. Besides suppressive pathways like for example the CD39/CD73 axis, mechanisms
Autor:
Julia Festag, Richard Klar, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Frank Jaschinski, Sandra Kallert, Sven Michel, Tamara Thelemann, Alfred Zippelius, Abhishek S. Kashyap, Stefanie Raith
Publikováno v:
Cancer Research. 79:5021-5021
The ectonucleotidases CD39 and CD73 have emerged as promising therapeutic targets to enhance antitumor immune responses, as they act in concert to convert extracellular immune-stimulating ATP to immunosuppressive adenosine. CD39 and CD73 are expresse